Due to high frequency of the Omicron variant, bamlanivimab and etesevimab are NOT currently authorized in any U.S. region. 

[FormWeb page pending further updates]

Administration Considerations:

Pediatric ED

• Use casirivimab/imdevimab (REGN-COV2)- may be administered subcutaneously (or IV).

Main ED/ ED OBS / OB ED

• Bamlanivimab-etesevimab preferred for IV orders 
• May use casirivimab/imdevimab (REGN-COV2) IV if needed
• May use casirivimab/imdevimab (REGN-COV2) subcutaneously if:
  • No IV access AND
  • Prescriber feels patient will not go to Fever & Flu Clinic for infusion

Inpatient (MAIN & HHWC)

• Must be administered as intravenous infusion
• Must meet all EUA criteria
  • Must NOT be admitted for treatment of COVID-19 nor have progressing COVID-19 symptoms
  • Presence of COVID19 is an incidental finding.

Reviewed: March 2021

Updated: September 2021

• Micromedex
• UpToDate
• Lippincott Advisor